<DOC>
	<DOCNO>NCT01469884</DOCNO>
	<brief_summary>Compare viral load hepatitis c virus patient convert certican versus patient maintain calcineurin inhibitor .</brief_summary>
	<brief_title>Effect Switching Certican® Viremia Hepatitis C Virus Adult Renal Allograft Recipients</brief_title>
	<detailed_description>The infection hepatitis C virus ( HCV ) lead cause chronic liver disease renal transplant recipient . The prevalence pretransplantation anti-HCV 11 % 49 % . The impact HCV infection patient survival renal transplant remain controversial . Some study also show patient undergo renal transplantation anti-HCV positive associate reduction graft patient survival.Chronic infection HCV associate increased number infection . In HCV positive renal transplant patient show increase four seven time HCV viremia transplantation compare pretransplant . To prevent viral replication , immunosuppression must adapt , involve balance control viral replication rejection . Biochemically , NS5A protein link increased replication hepatitis C virus p70S6K phosphopeptides . Sirolimus inhibitor pathway mTOR/p70S6K reduce vivo phosphorylation NS5A phosphopeptides thus viral replication . Moreover , mTOR protein proven vitron protective role apoptosis HCV infect cell ( WAGNER et al. , 2010 ) . Wagner et al . ( 2010 ) show beneficial effect sirolimus viral recurrence monitor transaminase viral load well histological data . They also report improved survival liver transplantation due hepatitis C patient receive sirolimus rather calcineurin inhibitor-based regimen . In literature already report good virological control HCV among liver transplant recipient conversion SRL reduction hepatitis C virus recurrence ( GALLEGO et al. , 2009 ; BENEDETTOET al. , 2010 ) . Everolimus show potent inhibitor mTOR widely use immunosuppressive agent kidney transplant , report effect HCV progression find literature .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Inclusion criterion Age ≥ 18 year time screening ; Subjects first tenth year renal transplantation ; Subjects positive serology hepatitis C ; Subjects receive calcineurin inhibitor ( tacrolimus cyclosporine ) plus mycophenolate sodium mofetil plus prednisone since first month posttransplant ; Subjects acute rejection episode last 3 month ; Women childbearing potential ( CBP ) negative pregnancy test screening ( urine serum ; Women CBP men sexual partner CBP must agree use medically acceptable method contraception throughout study . The investigator determine contraceptive method effective appropriate study subject . Acceptable method contraception include oral contraceptive , barrier method ( eg , diaphragm condom spermicide ) intrauterine device . Exclusion criterion : Subjects , opinion investigator , able complete study ; Recipients multiple organ transplant ( i.e. , prior concurrent transplantation nonrenal allograft ; Subjects calculate GFR &lt; 30ml/min ( abbreviate MDRD formula ; Subjects Urinary protein/creatinine &gt; 0.5 ; Renal biopsy score ≥ Banff grade II interstitial fibrosis tubular atrophy ( Banff 2007 ; Subjects history biopsyproven acute rejection within 12 week enrollment ; Known suspect hypersensitivity inhibitor mTOR ; Subjects history primary recurrent FSGS , membranous glomerulonephritis ( MGN ) membranoproliferative glomerulonephritis ( MPGN ) ; Evidence active systemic localize major infection ; Use investigational drug treatment 4 week enrollment ; Immunosuppressive therapy describe protocol ; Planned systemic treatment voriconazole , cisapride ketoconazole discontinue randomization ; Prior treatment aminoglycosides , amphotericin B , cisplatin drug associate renal dysfunction discontinue screen ; Subjects screen total white blood cell count ( WBC ) ≤ 2000/mm3 , hemoglobin ≤ 10g/dL platelet count ≤ 100000/mm3 ; TGO/AST , TGP/ALT bilirubins value three time high reference value ; Fasting triglycerides ≥ 400 mg/dL , fast total cholesterol ≥ 350 mg/dL LDLcholesterol ≥ 160mg/dL despite use optimal lipidlowering therapy ; History malignancy within 3 year enrollment adequately treat basal cell squamous cell carcinoma skin ; Subjects know human immunodeficiency virus ( HIV ) positive hepatitis B positive ; Chronic hepatic failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Renal allograft recipient</keyword>
	<keyword>Hepatitis C virus ( HCV )</keyword>
	<keyword>Certican</keyword>
	<keyword>Calcineurin inhibitor ( tacrolimus cyclosporin )</keyword>
</DOC>